Alimera Sciences (ALIM)
(Delayed Data from NSDQ)
$5.59 USD
+0.02 (0.36%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $5.58 -0.01 (-0.18%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum B VGM
Brokerage Reports
0 items in cart
Alimera Sciences, Inc. [ALIM]
Reports for Purchase
Showing records 61 - 80 ( 98 total )
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
UK Real-World Audit Data Demonstrate Improvement in Visual Acuity; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
UK Real-World Audit Data Demonstrate Improvement in Visual Acuity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Iluvien for Posterior Uveitis in EMEA In-Licensed From pSivida; Reiterate Buy and Raising Price Target to $5
Provider: Rodman & Renshaw, Co.
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Iluvien for Posterior Uveitis in EMEA In-Licensed From pSivida; Reiterate Buy and Raising Price Target to $5
Provider: H.C. Wainwright & Co., Inc.
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
It''s All About Sustained Delivery: ARVO 2017 Key Impressions
Provider: Rodman & Renshaw, Co.
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q17 Saw Growth in Revenue and User Demand; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q17 Saw Growth in Revenue and User Demand; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Real World Iluvien Data Presented at ARVO; 1Q17 Earnings Preview; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Real World Iluvien Data Presented at ARVO; 1Q17 Earnings Preview; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
A Commercial Steroid Implant for Diabetic Macular Edema- Initiating Coverage With Buy and $4 Price Target.
Provider: Rodman & Renshaw, Co.
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
A Commercial Steroid Implant for Diabetic Macular Edema; Initiating Coverage With Buy and $4 Price Target
Provider: H.C. Wainwright & Co., Inc.
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Termination of Coverage
Provider: RODMAN & RENSHAW, CO.
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Glimmers of hope for Iluvien .Waiting for further clarity on the U.S. path (if any)
Provider: RODMAN & RENSHAW, CO.
Analyst: KALIA S
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Glimmers of hope for Iluvien .Waiting for further clarity on the U.S. path (if any)
Provider: RODMAN & RENSHAW, CO.
Analyst: KALIA S
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
DCP announcement positive for Iluvien in Europe...Adopting a wait and see approach
Provider: RODMAN & RENSHAW, CO.
Analyst: KALIA S
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
DCP announcement positive for Iluvien in Europe...Adopting a wait and see approach
Provider: RODMAN & RENSHAW, CO.
Analyst: KALIA S
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alimera Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Downgrading to Market Perform based on second CRL....
Provider: RODMAN & RENSHAW, CO.
Analyst: KALIA S